Edition:
United States

Rocket Pharmaceuticals Inc (RCKT.OQ)

RCKT.OQ on NASDAQ Stock Exchange Global Market

18.79USD
4:00pm EDT
Change (% chg)

$-0.55 (-2.84%)
Prev Close
$19.34
Open
$19.39
Day's High
$19.78
Day's Low
$18.75
Volume
42,033
Avg. Vol
100,232
52-wk High
$25.85
52-wk Low
$7.96

Chart for

About

Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye. Its lead product candidate, trabodenoson, is a selective adenosine mimetic... (more)

Overall

Beta: 4.02
Market Cap(Mil.): $827.33
Shares Outstanding(Mil.): 39.66
Dividend: --
Yield (%): --

Financials

  RCKT.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -2.63 -- --
ROI: -28.49 1.96 12.83
ROE: -40.42 1.12 14.95

BRIEF-Rocket Pharmaceuticals Presents Updated Data From Phase 1/2 Gene Therapy Trial Of Rp-L102

* ROCKET PHARMACEUTICALS PRESENTS UPDATED DATA FROM PHASE 1/2 GENE THERAPY TRIAL OF RP-L102 IN PATIENTS WITH FANCONI ANEMIA AT THE AMERICAN SOCIETY OF GENE & CELL THERAPY (ASGCT) ANNUAL MEETING

May 18 2018

BRIEF-Rocket Pharmaceuticals Announces Strategic Research Collaboration

* ROCKET PHARMACEUTICALS ANNOUNCES STRATEGIC RESEARCH COLLABORATION

May 17 2018

BRIEF-Rocket Pharma Appoints Former FDA Staffer As VP Of Regulatory Policy And Patient Advocacy

* ROCKET PHARMACEUTICALS APPOINTS GAYATRI R. RAO, M.D., J.D., FORMER U.S. FOOD AND DRUG ADMINISTRATION DIRECTOR OF THE OFFICE OF ORPHAN PRODUCTS DEVELOPMENT, AS VICE PRESIDENT, REGULATORY POLICY AND PATIENT ADVOCACY Source text for Eikon: Further company coverage:

May 15 2018

BRIEF-Rocket Pharmaceuticals Reports Q1 Loss Per Share Of $0.42

* ROCKET PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

May 11 2018

Earnings vs. Estimates